Key highlights
- Nonclinical results showed reversal of cardiac glycogen accumulation and improvement in hypertrophy
- Company developed a new mouse model reproducing key PRKAG2 syndrome features including ECG abnormalities
- Data scheduled for presentation at the American Heart Association Scientific Sessions 2026 on November 6
- Corventis Phase 1/2 trial aims to enroll approximately 37 participants to evaluate safety and efficacy
- Cash runway expected to fund operations through 2028 following recent $50 million private placement
Nonclinical Findings and Presentation
Atrium Therapeutics disclosed new nonclinical data for ATR 1072, an investigational RNA therapy targeting the underlying genetic driver of PRKAG2 syndrome. In a company-developed mouse model, a single dose of a mouse-surrogate version of ATR 1072 led to the reversal of established cardiac glycogen accumulation and improvements in hypertrophy and electrocardiogram parameters. These results will be presented at the Hypertrophic Cardiomyopathy Medical Society during the American Heart Association Scientific Sessions 2026 in Chicago. The data reinforce the scientific rationale for targeting PRKAG2 mRNA to address the symptoms of this rare, early-onset cardiomyopathy.
Clinical and Operational Milestones
- Initial proof-of-concept data from the Corventis Phase 1/2 clinical trial is expected in the second half of 2027
- The Corventis trial is an open-label study evaluating safety, pharmacokinetics, and efficacy in 37 participants
- PRKAG2 syndrome currently has no approved therapies to address the genetic cause of the disease
- Atrium was established as an independent entity in February 2026 following a spin-off from Avidity Biosciences
- The company holds a cardiovascular collaboration with Bristol Myers Squibb, having earned $30 million in milestones this year
Chief Scientific Officer Perspective
“We are encouraged to see that a mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and improved other key features of the disease. These findings continue to strengthen the scientific rationale for ATR 1072.”
Financial Position and Market Context
Atrium Therapeutics maintains a market capitalization of approximately $141.5 million with a current share price of $8.27. In October 2026, the company secured a $50 million private placement of common stock and pre-funded warrants, which is expected to provide sufficient liquidity for operations through 2028. This financial stability supports the continued advancement of the Corventis trial and the broader targeted RNA delivery platform. The company reported annual revenue of $18.6 million for the prior period, largely driven by strategic partnership milestones, while continuing its focus on the precision cardiology sector.
Down 22.2% since our story on 2 Nov: $8.27 when we broke it → $6.43 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $7.61 |
|---|---|
| 20 Oct | $7.98 |
| 21 Oct | $8.00 |
| 22 Oct | $8.16 |
| 23 Oct | $8.20 |
| 26 Oct | $8.05 |
| 27 Oct | $8.32 |
| 28 Oct | $8.40 |
| 29 Oct | $8.26 |
| 30 Oct | $8.27 |
| 2 Nov | $8.55 |
| 3 Nov | $8.72 |
| 4 Nov | $8.68 |
| 5 Nov | $8.32 |
| 6 Nov | $8.34 |
| 9 Nov | $8.38 |
| 10 Nov | $8.23 |
| 11 Nov | $7.96 |
| 12 Nov | $7.50 |
| 13 Nov | $7.51 |
| 16 Nov | $6.43 |
| Date | Announcement | Amount |
|---|---|---|
| 27 Oct 2026 | Dosed first patient in the Phase 1/2 Corventis clinical trial of lead candidate ATR 1072 for PRKAG2 syndromeSource: investors.atriumtherapeutics.com | – |
| 08 Oct 2026 | Entered into a securities purchase agreement for a private placement of common stock and pre-funded warrantsSource: streetinsider.com | $50.0 Million |
| 13 Aug 2026 | Reported second quarter 2026 financial results and earned a second milestone payment from Bristol Myers SquibbSource: SEC filing | $15.0 Million |
| 14 Jul 2026 | Received U.S. FDA clearance of Investigational New Drug application for ATR 1072 to treat PRKAG2 syndromeSource: investors.atriumtherapeutics.com | – |
| 23 Apr 2026 | Earned first development milestone payment under cardiovascular collaboration with Bristol Myers SquibbSource: investors.atriumtherapeutics.com | $15.0 Million |
| 27 Feb 2026 | Launched as an independent publicly traded company following spin-off from Avidity BiosciencesSource: investors.atriumtherapeutics.com | $270.0 Million |
Management commentary
“Our new nonclinical model reproduced many features of PRKAG2 syndrome, including cardiac glycogen accumulation in the heart. We are encouraged to see that a mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and improved other key features of the disease.”
| Share price | $8.27 |
|---|---|
| Market cap | $141M |
| Revenue (annual) | $19M |
| 1-month price change | -0.12% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Atrium Therapeutics, Inc. announcing nonclinical data for ATR 1072 for the treatment of PRKAG2 syndrome.
Track Atrium Therapeutics, Inc. live
Get the next Atrium Therapeutics, Inc. SEC filing seconds after it lands.
